Supplemental table 2. Details of ANCOVA analysis in each study

| | Number of patients (AQPAD+NMOSD vs MS) | *P* value | |
|---|---|---|---|
| | | of the parallel slopes assumption | after ANCOVA |
| **NBV** in **study 1** using controlled for factors significant different | | | |
| OCB included | 27 vs 49 | 0.80 | 0.24 |
| OCB excluded | 36 vs 60 | 0.64 | 0.45 |
| **NGV** in **study 1** using controlled for factors significant different | | | |
| OCB included | 27 vs 49 | 0.99 | 0.53 |
| OCB excluded | 36 vs 60 | 0.70 | 0.82 |
| **NWV** in **study 1** using controlled for factors significant different | | | |
| OCB included | 27 vs 49 | 0.24 | 0.061 |
| OCB excluded | 36 vs 60 | 0.30 | 0.091 |
| **NBV** in **study 2** using controlled for factors significant different | | | |
| OCB included | 19 vs 36 | 0.64 | 0.18 |
| OCB excluded | 27 vs 45 | 0.073 | 0.29 |
| **NGV** in **study 2** using controlled for factors significant different | | | |
| OCB included | 19 vs 36 | 0.93 | 0.25 |
| OCB excluded | 27 vs 45 | 0.19 | 0.34 |
| **NWV** in **study 2** using controlled for factors significant different | | | |
| OCB included | 19 vs 36 | 0.030* | Not obtained |
| OCB excluded | 27 vs 45 | 0.002* | Not obtained |

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

*J Neurol Neurosurg Psychiatry*

| | | | | |
|---|---|---|---|---|
| **NBV** in **study 3** using controlled for factors significant different | | | | |
| | OCB included | 18 vs 20 | 0.31 | 0.31 |
| | OCB excluded | 20 vs 20 | 0.65 | 0.13 |
| **NGV** in **study 3** using controlled for factors significant different | | | | |
| | OCB included | 18 vs 20 | 0.15 | 0.34 |
| | OCB excluded | 20 vs 20 | 0.63 | 0.79 |
| **NWV** in **study 3** using controlled for factors significant different | | | | |
| | OCB included | 18 vs 20 | 0.80 | 0.96 |
| | OCB excluded | 20 vs 20 | 0.97 | 0.85 |

*$P < 0.05$.

ANCOVA: an analysis of covariance: AQP4+NMOSD: anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder disease; DMD: disease modifying drug; MS: multiple sclerosis. NBV: normalized brain volume; NGV: normalized grey matter volume; NLV: normalized lesion volume; NWV: normalized white matter volume; OCB: oligoclonal bands.

We performed with or without some significant different items because the number of samples were changed due to them.